Loading
A bispecific ADC is an ADC whose antibody grabs two different proteins on the cancer cell, so it sticks better to tumour and less to healthy tissue.
Izalontamab brengitecan (iza-bren, EGFR×HER3, SystImmune/BMS) is the first bispecific ADC with positive phase 3 results, meeting PFS and OS in previously treated TNBC (BL-B01D1-307, February 2026) and in oesophageal cancer, with first-line trials (IZABRIGHT-Breast01) ongoing. Eight bsADC phase 3 trials started in 2025. c-MET×EGFR is the most crowded pair (tilatamig samrotecan, AZD9592, 24 candidates); Nectin-4×TROP2 (AK146D1, AVZO-103), HER2 biparatopic (zanidatamab zovodotin), and PD-L1×B7-H3 (BH4601) follow.
Dual antigen binding increases avidity and internalisation and can enable lysosomal trafficking (e.g., pairing with a rapidly internalising receptor). Biparatopic designs cross-link one receptor.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
AK146D1 is Akeso's Nectin-4 × TROP2 bispecific ADC, combining the two most validated ADC addresses in one molecule.
Izalontamab brengitecan is the first bispecific ADC to succeed in a phase 3 trial, hitting two growth receptors at once in triple-negative breast cancer.
AstraZeneca's EGFR×c-MET bispecific ADC, the most advanced in the most crowded next-generation ADC target pair.
Query for this technology: (TITLE:"bispecific antibody-drug conjugate" OR ABSTRACT:"bispecific antibody-drug conjugate" OR TITLE:"bispecific ADC" OR ABSTRACT:"bispecific ADC"). Results are unfiltered search hits about Bispecific ADC, not a curated reading list.
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, TROP2, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag frontier.
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Acquired resistance to every therapy, Antibody-drug conjugate (ADC) and the tag frontier.
Shares Logic-gated therapeutics (AND, NOT gates), ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares Nectin-4, B7-H3, Bladder & urothelial cancer and the tag frontier.
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, HER2, Antibody-drug conjugate (ADC) and the tag frontier.
Shares Acquired resistance to every therapy, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag frontier.
Shares Logic-gated therapeutics (AND, NOT gates), Bristol Myers Squibb and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.